www.fdanews.com/articles/123716-sciclone-sigma-tau-report-positive-results-from-influenza-vaccine-trial
SciClone, Sigma-Tau Report Positive Results From Influenza Vaccine Trial
January 15, 2010
SciClone Pharmaceuticals and its partner Sigma-Tau have received
initial topline results in a clinical study valuating the potential of Zadaxin to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent
vaccine, Focetria from Novartis.
Trading Markets
Trading Markets